Nanoviricides Financials
This page shows Nanoviricides (NNVC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash burn funded by equity is the core mechanic as research spending stays high and liquidity thins.
From FY2023 to FY2025, operating cash flow stayed close to the net loss; in FY2025 they were-$8.5M and-$9.5M . With capex only$57K and free cash flow nearly identical to operating cash flow, the burn is coming from running the organization, not from building a larger asset base.
Cash reserves fell from
FY2024 and FY2025 brought financing inflows of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Nanoviricides's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nanoviricides carries a low D/E ratio of 0.17, meaning only $0.17 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
Nanoviricides's current ratio of 1.28 is below the typical benchmark, resulting in a score of 21/100. However, the company holds substantial cash reserves (119% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
Nanoviricides generates a -125.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -72.4% the prior year.
Nanoviricides passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Nanoviricides generates $0.90 in operating cash flow (-$8.5M OCF vs -$9.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Nanoviricides earns $-64373.5 in operating income for every $1 of interest expense (-$9.6M vs $149). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Nanoviricides generated $0 in revenue in fiscal year 2025.
Nanoviricides's EBITDA was -$8.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.1% from the prior year.
Nanoviricides reported -$9.5M in net income in fiscal year 2025. This represents a decrease of 14.1% from the prior year.
Nanoviricides earned $-0.63 per diluted share (EPS) in fiscal year 2025. This represents an increase of 10.0% from the prior year.
Cash & Balance Sheet
Nanoviricides generated -$8.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 31.9% from the prior year.
Nanoviricides held $1.6M in cash against $0 in long-term debt as of fiscal year 2025.
Nanoviricides had 17M shares outstanding in fiscal year 2025. This represents an increase of 26.3% from the prior year.
Margins & Returns
Nanoviricides's ROE was -125.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 53.6 percentage points from the prior year.
Capital Allocation
Nanoviricides invested $5.5M in research and development in fiscal year 2025. This represents an increase of 2.1% from the prior year.
Nanoviricides invested $57K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 63.6% from the prior year.
NNVC Income Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $0 | N/A | N/A | N/A | $0 | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.3M+15.0% | $1.1M+12.6% | $993K | N/A | $1.3M+10.9% | $1.2M-40.2% | $1.9M | N/A |
| SG&A Expenses | $744K-33.2% | $1.1M+38.7% | $804K | N/A | $967K+7.1% | $903K-26.9% | $1.2M | N/A |
| Operating Income | -$2.0M+9.1% | -$2.2M-24.3% | -$1.8M | N/A | -$2.2M-9.2% | -$2.1M+35.0% | -$3.2M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $149 | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.0M+10.4% | -$2.2M-24.4% | -$1.8M | N/A | -$2.2M-9.3% | -$2.0M+35.2% | -$3.1M | N/A |
| EPS (Diluted) | $-0.09+18.2% | $-0.11-10.0% | $-0.10 | N/A | $-0.140.0% | $-0.14+39.1% | $-0.23 | N/A |
NNVC Balance Sheet
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.2M-16.7% | $12.3M+46.8% | $8.4M-5.3% | $8.8M-12.0% | $10.0M-13.3% | $11.6M-1.4% | $11.7M-8.4% | $12.8M |
| Current Assets | $3.4M-36.2% | $5.3M+322.9% | $1.3M-25.0% | $1.7M-38.7% | $2.7M-33.0% | $4.1M+0.8% | $4.0M-18.7% | $5.0M |
| Cash & Equivalents | $3.2M-37.6% | $5.2M+357.5% | $1.1M-27.8% | $1.6M-38.7% | $2.5M-35.8% | $4.0M+2.4% | $3.9M-19.4% | $4.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.1M-8.3% | $1.2M0.0% | $1.2M-7.7% | $1.3M+8.4% | $1.2M-0.1% | $1.2M-26.5% | $1.6M+20.2% | $1.4M |
| Current Liabilities | $1.1M-10.9% | $1.2M+1.1% | $1.2M-9.5% | $1.3M+9.0% | $1.2M+1.3% | $1.2M-27.5% | $1.6M+20.2% | $1.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $9.2M-17.3% | $11.1M+54.3% | $7.2M-4.6% | $7.5M-14.9% | $8.8M-15.0% | $10.4M+2.8% | $10.1M-11.8% | $11.5M |
| Retained Earnings | -$154.8M-1.3% | -$152.8M-1.5% | -$150.6M-1.2% | -$148.8M-1.4% | -$146.7M-1.5% | -$144.5M-1.4% | -$142.5M-2.2% | -$139.4M |
NNVC Cash Flow Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.9M+5.8% | -$2.0M-28.6% | -$1.6M+6.3% | -$1.7M+14.5% | -$2.0M+9.1% | -$2.2M+15.6% | -$2.6M-75.2% | -$1.5M |
| Capital Expenditures | $0+100.0% | -$1-100.0% | $84K+726.6% | $10K | $0 | $0-100.0% | $47K-52.4% | $98K |
| Free Cash Flow | -$1.9M+5.8% | -$2.0M-22.1% | -$1.7M+2.0% | -$1.7M+14.0% | -$2.0M+9.1% | -$2.2M+17.1% | -$2.6M-67.2% | -$1.6M |
| Investing Cash Flow | $0-100.0% | $1+100.0% | -$84K-726.6% | -$10K | $0 | $0+100.0% | -$47K+52.4% | -$98K |
| Financing Cash Flow | -$7K-100.1% | $6.1M+387.8% | $1.2M+71.0% | $728K+26.5% | $576K-74.8% | $2.3M+33.5% | $1.7M-45.2% | $3.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NNVC Financial Ratios
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -21.7%-1.7pp | -20.1%+4.8pp | -24.9% | N/A | -25.1%-5.6pp | -19.5%+11.4pp | -30.9% | N/A |
| Return on Assets | -19.5%-1.4pp | -18.1%+3.3pp | -21.4% | N/A | -22.1%-4.6pp | -17.5%+9.1pp | -26.6% | N/A |
| Current Ratio | 3.17-1.3 | 4.43+3.4 | 1.06-0.2 | 1.28-1.0 | 2.27-1.2 | 3.44+1.0 | 2.48-1.2 | 3.66 |
| Debt-to-Equity | 0.12+0.0 | 0.11-0.1 | 0.170.0 | 0.17+0.0 | 0.14+0.0 | 0.12-0.0 | 0.16+0.0 | 0.12 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Nanoviricides's annual revenue?
Nanoviricides (NNVC) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Nanoviricides profitable?
No, Nanoviricides (NNVC) reported a net income of -$9.5M in fiscal year 2025.
What is Nanoviricides's EBITDA?
Nanoviricides (NNVC) had EBITDA of -$8.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nanoviricides's return on equity (ROE)?
Nanoviricides (NNVC) has a return on equity of -125.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nanoviricides's free cash flow?
Nanoviricides (NNVC) generated -$8.5M in free cash flow during fiscal year 2025. This represents a -31.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nanoviricides's operating cash flow?
Nanoviricides (NNVC) generated -$8.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nanoviricides's total assets?
Nanoviricides (NNVC) had $8.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nanoviricides's capital expenditures?
Nanoviricides (NNVC) invested $57K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Nanoviricides spend on research and development?
Nanoviricides (NNVC) invested $5.5M in research and development during fiscal year 2025.
What is Nanoviricides's current ratio?
Nanoviricides (NNVC) had a current ratio of 1.28 as of fiscal year 2025, which is considered adequate.
What is Nanoviricides's debt-to-equity ratio?
Nanoviricides (NNVC) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nanoviricides's return on assets (ROA)?
Nanoviricides (NNVC) had a return on assets of -107.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nanoviricides's cash runway?
Based on fiscal year 2025 data, Nanoviricides (NNVC) had $1.6M in cash against an annual operating cash burn of $8.5M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Nanoviricides's Piotroski F-Score?
Nanoviricides (NNVC) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nanoviricides's earnings high quality?
Nanoviricides (NNVC) has an earnings quality ratio of 0.90x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Nanoviricides cover its interest payments?
Nanoviricides (NNVC) has an interest coverage ratio of -64373.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Nanoviricides?
Nanoviricides (NNVC) scores 20 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.